Sandoz reports sales of $2.49 billion for the first quarter of 2024, up 5% on a reported basis and 6% at constant exchange rates, with all geographic regions contributing to growth.

The Swiss healthcare group points out that sales of biosimilars enjoyed another quarter of double-digit growth (+21%), while sales of generic drugs remained in line with the previous year's level.

Sandoz reiterates its full-year guidance for 2024, expecting sales to grow in the mid-single digits at constant exchange rates, and a core EBITDA margin of around 20%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.